Epidemiology and Risk Factors for Giant Coronary Artery Aneurysms Identified After Acute Kawasaki Disease
- PMID: 33682062
- DOI: 10.1007/s00246-021-02571-8
Epidemiology and Risk Factors for Giant Coronary Artery Aneurysms Identified After Acute Kawasaki Disease
Abstract
A giant coronary artery (CA) aneurysm is a potentially fatal cardiac complication resulting from Kawasaki disease (KD). We aimed to identify epidemiologic characteristics and potential risk factors associated with giant CA aneurysms identified after acute KD. We analyzed 90,252 patients diagnosed with KD from 2011 to 2018, using data obtained in nationwide KD surveys conducted in Japan. Multivariable logistic regression analyses were performed to evaluate potential risk factors associated with subsequent giant CA aneurysm complications (defined as lumen size ≥ 8 mm), adjusting for all potential factors. Giant CA aneurysms were identified in 144 patients (0.16%) after acute KD. The annual prevalence ranged from 0.07 to 0.20% during the study period. In the multivariate analyses, male sex (adjusted odds ratio 2.09 [95% confidence interval 1.41-3.11], recurrent KD (1.90 [1.09-3.33]), IVIG administration at 1-4 days of illness (1.49 [1.04-2.15]) and ≥ 8 days after KD onset (2.52 [1.38-4.60]; reference, 5-7 days), detection of CA dilatations and aneurysms at initial echocardiography (4.17 [1.85-5.41] and 46.5 [28.8-74.8], respectively), and resistance to IVIG treatment (6.09 [4.23-8.75]) were significantly associated with giant CA aneurysm complications identified after acute KD. The annual prevalence of giant CA aneurysms identified after acute KD did not increase during the study period. Patients with larger CA abnormalities detected at initial echocardiography were independently associated with progression to giant CA aneurysm complications after acute KD regardless of the number of days from onset at treatment initiation.
Keywords: Cardiac complication; Coronary artery abnormality; Coronary artery aneurysm; Coronary artery dilatation; Giant coronary artery aneurysm; Kawasaki disease.
References
-
- JCS Joint Working Group (2014) Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ J 78(10):2521–2562. https://doi.org/10.1253/circj.cj-66-0096 - DOI
-
- Ae R, Makino N, Kosami K, Kuwabara M, Matsubara Y, Nakamura Y (2020) Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: the nationwide survey in Japan, 2017–2018. J Pediatr. https://doi.org/10.1016/j.jpeds.2020.05.034 - DOI - PubMed
-
- McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135(17):e927–e999. https://doi.org/10.1161/cir.0000000000000484 - DOI - PubMed
-
- Newburger JW, Takahashi M, Burns JC (2016) Kawasaki disease. J Am CollCardiol 67(14):1738–1749. https://doi.org/10.1016/j.jacc.2015.12.073 - DOI
-
- Burns JC, Glodé MP (2004) Kawasaki syndrome. Lancet 364(9433):533–544. https://doi.org/10.1016/s0140-6736(04)16814-1 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources